Sparsh Bio-Tech Private Limited - Due diligence report

A 360° intelligence report on Sparsh Bio-Tech: trust score, financial health, credit view, compliance, directors, growth and distress signal…

2001-03-30 District Jamnagar, Gujarat Active Unlisted Active Compliant
Share
Connect MCP
SB Sparsh Bio-Tech Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Sparsh Bio-Tech — 360° Intelligence Report

Generated from MCA filings & public records
79/100
Trust Score
Low Risk

Sparsh Bio-Tech is assessed as Low Risk with a Trust Score of 79/100. Sparsh Bio-Tech is an active private limited indian non-government company incorporated in 2001, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 10 Aug 2026 from the latest processed filings. Sparsh Bio-Tech Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
79/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
66/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
75/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 75/100 Low Risk
  • Moderate gearing (D/E 38%).
  • Profitable - internal accruals available.

Charges position: 2 open (25.79 cr) · 3 satisfied (3.05 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others1 48.0 cr
Oriental Bank Of Commerce3 48.0 cr
Axis Bank Limited1 48.0 cr
Compliance Score: 66/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 2 court forum(s).
  • Delayed payments to MSME suppliers disclosed (122 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RASIK HIRJI HARIA 01234567 Director 01/04/2018 6 yrs Approved
ASHOK JUTHALAL MARU 01234567 Director 01/04/2018 6 yrs Approved
SUNDEEP PREMCHAND MARU 01234567 Director 01/04/2018 6 yrs Approved
PARAS JUTHALAL MARU 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 0 transfer(s)

Key managerial personnel: ASHOK JUTHALAL MARU (Managing Director) · SUNDEEP PREMCHAND MARU (Whole-time director) · PARAS JUTHALAL MARU (Whole-time director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 65 · Distress 75
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 25+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
2 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 2.01 cr.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence73/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment73/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 25.79 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view72/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
09 Jun 2020
Charge created
Axis Bank Limited - 49.00 Lakh
01 Apr 2014
Director ceased
SUNDEEP PREMCHAND MARU
22 Jul 2010
Securities allotted
151700 Equity Shares Without Differential Rights - 15.17 Lakh raised
28 Jan 2010
Securities allotted
890500 Equity Shares Without Differential Rights - 89.05 Lakh raised
30 May 2008
Charge created
Others - 25.30 cr
29 May 2008
Charge satisfied
Oriental Bank Of Commerce
01 Apr 2006
Director ceased
PARAS JUTHALAL MARU
30 Sep 2005
Director appointed
SUNDEEP PREMCHAND MARU (Whole-time director)
01 Apr 2003
Director appointed
PARAS JUTHALAL MARU (Whole-time director)
17 Dec 2002
Charge created
Oriental Bank Of Commerce - 63.04 Lakh
Charge created
Oriental Bank Of Commerce - 1.17 cr
Charge created
Oriental Bank Of Commerce - 1.25 cr
03 Nov 2001
Director appointed
RASIK HIRJI HARIA (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - manageable leverage.
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Rajsha Chemicals Private Limited U24110GJ1989PTC011849 Baroda, Gujarat, India
Ramcides U24117TN1994PTC029550 Chennai, Tamil Nadu, India
Black Rose L17120MH1990PLC054828 Mumbai, Maharashtra, India
Bansal Alkalies Private Limited U24100GJ2011PTC063955 Ahmedabad, Gujarat, India
Aksharchem L24110GJ1989PLC012441 Indrad, Gujarat, India
D R Coats Ink And Resins Private Limited U24220MH2003PTC142114 Mumbai, Maharashtra, India
Ellenbarrie Industrial Gases L24112WB1973PLC029102 Kolkata, West Bengal, India
Geno Pharmaceuticals U24239GA1975PTC000250 Goa, Goa, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Sparsh Bio-Tech before audits and certifications: compliance score 66/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Sparsh Bio-Tech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 75/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 65/100, margin trends, ownership structure and peer set for Sparsh Bio-Tech - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 79/100, distress signals and MSME payment-delay disclosures - know whether Sparsh Bio-Tech pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Sparsh Bio-Tech - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Sparsh Bio-Tech an active company?

Sparsh Bio-Tech has MCA status “Active” with a compliance score of 66/100 (Moderate).

Is Sparsh Bio-Tech financially healthy?

Sparsh Bio-Tech has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.

Should I do business with Sparsh Bio-Tech?

Its overall Trust Score is 79/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Sparsh Bio-Tech?

See the directors and ownership sections above for board and shareholding detail. 4 active director(s) are on record.

Does Sparsh Bio-Tech have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.

Is Sparsh Bio-Tech up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 66/100 (Moderate).

Is it risky to lend to Sparsh Bio-Tech?

Its Credit Risk Score is 75/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.